Skip to main content
. 2014 Jun 2;111(24):E2482–E2491. doi: 10.1073/pnas.1323681111

Fig. 2.

Fig. 2.

Deletion of 11β-HSD1 ameliorates the adverse metabolic side-effect profile induced by CORT. C57BL/6 WT (white bars) and 11β-HSD1 KO mice (GKO, black bars) were treated with CORT (100 μg/mL) or vehicle via the drinking water for 5 wk (n = 7–9 in each group). Glucose tolerance (A), calculated area under the curve (AUC) for glucose tolerance data (B), fasting insulin levels (C), fasting glucose (D), HOMA-IR index (E), and systolic blood pressure (BP) (F) were improved in CORT-treated GKO mice compared with CORT-treated WTs. Data were analyzed using two-way ANOVA; see Fig. S1 for the complete dataset used in the analysis. **P < 0.01, ***P < 0.001 vs. WT vehicle; ∅P < 0.05, ∅∅P < 0.01, ∅∅∅P < 0.001 vs. WT CORT.